Having recently proved SapC-DOPS efficacy against orthotopic U87ΔEGFR GBM tumor xenografts with constitutive EGFR activation [11], in this report we assessed SapC-DOPS' antitumor actions on non-genetically engineered U87-MG GBM cell xenografts. Here, EGFR is linked to glioblastoma.